Loading…
← CockpitCompetitor Analysis › 3880.HK Medtide, Inc. Class HOpen in the cockpit ↗

Medtide, Inc. Class H3880.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Momentum neutral 46
Mkt cap
$331M
US dollars, full cap
Free float
9%
of shares outstanding
$/day
$282,291
20-day average traded
Fwd P/E
10.5×
forward earnings
ROIC−WACC
+18.8 pp
WACC 5.6%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · HKDHK$18.55
1D-2.2%
1W-5.4%
1M-5.7%
3M-17.2%
6M-16.7%
YTD-39.1%
1Y-39.4%
ATR %5.2%
52w lowhigh42.0% off high

What Medtide does

Employees: 566

Medtide at a glance

Size Medtide (3880.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $331M, the 859th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$18.55 on 18 Nov 2026.

Performance Over six months the shares fell 16.7%, against -31.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue grew 14.0% over the last twelve months (peer median +5.7%); the operating margin is 35.9% (peer median -244.5%).

Valuation It trades at 10.5× forward earnings.

Capital Return on invested capital runs 18.8 points above its cost of capital (5.6% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 20263880.HK 85Peer median 69
Six months, rebased to 100: Medtide against the median of its 20 peers (local-currency closes).

Medtide financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$614MHK$618MHK$479MHK$372MHK$408M
Revenue growth—+29%+29%-9%—
Gross profitHK$381MHK$392MHK$271MHK$199MHK$234M
EBITDAHK$254MHK$280MHK$173MHK$126MHK$162M
Net incomeHK$187MHK$236MHK$64.2MHK$54.0MHK$62.8M
Free cash flow-HK$74.1MHK$149MHK$107MHK$36.6MHK$48.6M
Capital expenditureHK$216MHK$141MHK$24.3MHK$61.5MHK$107M
Total debtn/aHK$34.2MHK$36.7MHK$332MHK$365M

Quarterly statements and history in the cockpit →

Medtide competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-25%0%+25%2105LRMRCCCC358570LYEL69457630PROK086900NAUT4894CRMD1873CTNMGLSIGALT4760603880.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Medtide is the large dot.

Fundamentals: revenue growth against valuation

+5%+10%10×15×08690018733880.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Medtide is the large dot.

Medtide competitors and peer comparison

How Medtide compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Medtide against its 20 peers (data as of 18 Nov 2026)
Measure3880.HKPeer medianRank in peer set
1-month return-5.7%-4.7%10th lowest of 20
6-month return-16.7%-31.0%5th highest of 20
Distance from 52-week high-42.0%-54.6%4th highest of 20
Revenue growth (TTM)+14.0%+5.7%5th highest of 13
Operating margin35.9%-244.5%2nd highest of 15
Forward P/E10.5×n/a—
ROIC minus cost of capital+18.8 pp-63.8 pp3rd highest of 14
EV / EBITDA5.8×12.4×3rd cheapest of 6
Net debt / EBITDA-4.5×-1.1×least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Medtide 3880.HKHong Kong$331M-17%+14%36%10.5×n/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%n/an/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%n/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%n/an/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%n/an/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%n/an/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%n/an/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%18.1×4.7%+11.9%
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%n/an/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%n/an/an/a
CorMedix CRMDUnited States$358M-43%+92%39%n/an/an/a
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%n/an/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%8.1×2.6%+19.1%
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a
Galectin Therapeutics GALTUnited States$301M+35%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%n/a0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%n/an/an/a

Questions

Which companies are Medtide's closest peers?
The cockpit's peer set: Laekna (2105.HK), Larimar Therapeutics (LRMR), C4 Therapeutics (CCCC), GI Innovation (358570.KS), Lyell Immunopharma (LYEL), AP Biosciences (6945.TWO), IMPACT Therapeutics (7630.HK), ProKidney (PROK).
How has Medtide stock performed?
Over six months to 18 Nov 2026 the shares returned -16.7% against -31.0% for the median peer; over one year -39.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.